The use of Favipiravir Compared to Standard of Care in Hospitalized Subjects with COVID-19
If you choose to take part in this study, you will be placed in one of the study groups and either receive the study drug with our standard care (the things we currently do at BMC for coronavirus patients) or standard care by itself with no study drug. Whether you receive study drug with standard care or standard care only is based on chance (like tossing a coin).
If you decide to join this research study, the following things will happen: review of medical history and concomitant medications, physical exam, assessment of vital signs, blood sample collection, urine or blood pregnancy test (if you are a woman of childbearing age), taking the study drug twice daily by mouth, and nasopharyngeal (nose) and oropharyngeal (mouth) swabs.
It will take 60 days to complete the study. During this time, we will ask to monitor you during your inpatient stay and will ask you to make up to nine study visits (depending on when you are discharged) to the Boston Medical Center.
At the end of the study, we will compare the results from people who received the study drug with the results from people who received standard care.
You may (or may not) not benefit from taking part in this research study. If you receive favipiravir, it is possible that your COVID-19 symptoms will improve while you are taking it.
- Adults 18-80 years old within 72 hours of hospitalization for COVID-19
In this research study we want to learn more about the drug favipiravir and the effect it has when combined with the standard of care treatment for patients with coronavirus disease (COVID-19).
About 50 subjects will take part in this research study. About 10 volunteers will take part at Boston Medical Center (BMC). The study doctor will determine whether you qualify to participate in the study based upon the results from your screening visit.